Patent 9181319 was granted and assigned to Moderna Therapeutics on November, 2015 by the United States Patent and Trademark Office.
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.